Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $26.60.

A number of research firms have issued reports on ATXS. Wedbush restated an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Finally, JMP Securities began coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an "outperform" rating and a $26.00 price objective on the stock.

Astria Therapeutics Price Performance

ATXS traded down $0.36 on Friday, hitting $5.34. The company had a trading volume of 450,105 shares, compared to its average volume of 404,676. The stock has a market cap of $301.36 million, a price-to-earnings ratio of -2.56 and a beta of 0.69. The company's fifty day moving average price is $6.81 and its 200 day moving average price is $9.13. Astria Therapeutics has a 1-year low of $5.29 and a 1-year high of $14.04.

Remove Ads

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. On average, sell-side analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its position in Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock worth $556,000 after purchasing an additional 1,381 shares during the period. Hsbc Holdings PLC raised its stake in shares of Astria Therapeutics by 9.0% in the 4th quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company's stock valued at $170,000 after buying an additional 1,587 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Astria Therapeutics by 7.6% during the 4th quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 2,222 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Astria Therapeutics by 19.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company's stock valued at $159,000 after acquiring an additional 2,878 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.